Study of 2141-V11 for esophageal, stomach, or junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called 2141-V11 in people with advanced esophageal, stomach, or gastroesophageal junction cancer. It aims to see if adding this drug to your current treatment can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma (a type of cancer) of the esophagus, stomach, or gastroesophageal junction.
- Your cancer is locally advanced (cannot be removed with surgery) or has spread to other parts of the body.
- You have been on your first line of treatment, which includes a chemotherapy drug called fluoropyrimidine and an immunotherapy drug (anti-PD-1), for at least 3 months but no more than 9 months.
- Your primary tumor must still be visible during an endoscopy (a procedure using a camera to look inside your digestive tract).
- You are 18 years or older and able to perform daily activities with minimal help (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This trial tests a new drug (ONO-4578) combined with the usual immunotherapy (nivolumab) and chemotherapy for stomach cancer that has not been treated before. It aims to see if adding this drug helps shrink tumors or slows disease growth better than placebo.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.